FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] SMITH SANDFORD D						2. Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [CYTK]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 01/02/2013								Office below	r (give title ′)		Other (below)	specify
280 EAST GRAND AVENUE					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable				
(Street) SOUTH SAN FRANCISCO CA 94080													Ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Exe if a	Deeme ecution l ny onth/Day	Date,	Transaction D Code (Instr. a			4. Securities Acquired Disposed Of (D) (Instr. and 5)		Securit Benefic Owned	neficially ned		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership	
								Code \	,	Amount	(A) c (D)	Price	Report Transa	Following Reported Transaction(s) (Instr. 3 and 4)		tr. 4)	(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion Date Execution Date, or Exercise (Month/Day/Year) Price of Derivative		on Date,			of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Non- Qualified Stock Option (right to buy)	\$0.6702	01/02/2013			Α		65,279		02/02/2013 ⁽¹⁾	01	1/02/2023	Common Stock	65,279	\$0.2681 ⁽²⁾	65,279)	D	
Non- Qualified Stock Option (right to buy)	\$0.91								06/22/2012 ⁽³⁾	05	5/22/2022	Common Stock	25,000		25,000)	D	
Non- Qualified Stock Option (right to buy)	\$1.05								04/05/2012 ⁽⁴⁾	03	3/05/2022	Common Stock	40,000		40,000)	D	
Non- Qualified Stock Option (right to buy)	\$1.14								05/02/2012 ⁽⁵⁾	04	4/02/2022	Common Stock	16,447		16,447	7	D	

Explanation of Responses:

1. This option shall vest and become exercisable as to 65,279 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2014.

2. This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of \$35,000.

3. This option shall vest and become exercisable as to 25,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 22, 2013.

4. This option shall vest and become exercisable as to 40,000 shares divided into equal monthly installments such that the option shall be 100% vested on March 5, 2015.

5. This option shall vest and become exercisable as to 16,447 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2013.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.